⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10129899 | 1.00 | — | — | |
| SCHEMBL9925501 | 1.00 | — | — | |
| SCHEMBL14792301 | 0.89 | DRD2 (0.50) | — | |
| SCHEMBL17308793 | 0.87 | DRD2 (0.45) | — | |
| SCHEMBL11929534 | 0.86 | GNAI3 (0.50) | — | |
| SCHEMBL11929529 | 0.86 | GNAI3 (0.50) | — | |
| SCHEMBL9925579 | 0.85 | DRD2 (0.48) | — | |
| SCHEMBL20324860 | 0.85 | GNAO1 (0.58) | — | |
| SCHEMBL21759481 | 0.83 | GNAO1 (0.61) | — | |
| SCHEMBL21933451 | 0.83 | GNAO1 (0.61) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2024015864-A1 | CBL-B INHIBITORS AND ANTI-PD1/ANTI-PD-L1 FOR USE IN THE TREATMENT OF CANCER | HOTSPOT THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2023171736-A1 | MEDICINE CONTAINING VITAMIN D DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, USED IN COMBINATION WITH IMMUNOMODULATORY SUBSTANCE | 帝人ファーマ株式会社 | 2023-09-14 | — | — | WO | disclosed |
| WO-2023134698-A1 | PYRIDAZINE-1(6H)-6-OXO COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 深圳信立泰药业股份有限公司 | 2023-07-20 | — | — | WO | disclosed |
| US-20230149399-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | USHER III INITIATIVE, INC. | 2023-05-18 | — | — | US | disclosed |
| WO-2022098970-A9 | PYRAZOLE DERIVATIVES AS RET KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023015240-A1 | TRICYCLIC FUSED PYRIMIDINE COMPOUNDS FOR USE AS HER2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-02-09 | — | — | WO | disclosed |
| WO-2022098970-A1 | PYRAZOLE DERIVATIVES ASR ET KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022059684-A1 | VITAMIN D DERIVATIVE HAVING CYCLIC AMINE IN SIDE CHAIN | 帝人ファーマ株式会社 | 2022-03-24 | — | — | WO | disclosed |
| WO-2022011091-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | USHER III INITIATIVE, INC. (US) | 2022-01-13 | — | — | WO | disclosed |
| US-8022059-B2 | Indazole acrylic acid amide compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20110086836-A1 | Substituted Phenylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2011-04-14 | — | — | US | disclosed |
| US-20110086836-A1 | Substituted Phenylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2011-04-14 | — | — | US | disclosed |
| US-20100261714-A1 | INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261714-A1 | INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20100256108-A1 | INDAZOLE ACRYLIC ACID AMIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100168076-A1 | DIPHENYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME CORP. | 2010-07-01 | — | — | US | disclosed |
| US-20090258851-A1 | DIARYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| WO-2009015867-A1 | SUBSTITUTED ARYL OR HETEROARYLPIPERDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2009-02-05 | — | — | WO | disclosed |
| EP-2020405-A1 | Substituted aryl or heteroarylpiperidine derivatives as melanocortin-4 receptor modulators | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2009-02-04 | — | — | EP | disclosed |